We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) ...
Today is shaping up negative for Silence Therapeutics plc (NASDAQ:SLN) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian ...
SLN is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of SLN shares has decreased $0.08 since the market last closed. This is a 1.09% ...
Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback